Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Exclusion Criteria

• •1. Patients must complete Stage 2 of the core study B2335S (NCT00463567).
• •2. Written informed consent to participate in the extension must be obtained.
• •3. Patients must be able to comply with all study requirements.
• •Patients who were randomized to open-label tiotropium in Study B2335S.
• •Patients who participated in Stage 1 of the core study (B2335S).
• •Patients discontinued irrespective of the reason from Stage 2 of the core study.
• •Patients who fail to comply with the core protocol requirements and procedures.
• •Concomitant medical conditions that may interfere with interpretation of study results as defined in the core study protocol.
• •Patients who in the Investigator's opinion should not participate in the extension study.